CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and ...
Cancer treatment has evolved tremendously over the past decades with new treatments like immune checkpoint inhibitors, which can activate the immune system to kill tumor cells, providing some of the ...
-Publication shows picomolar affinity for CCR8 with no off-target binding and proof-of- mechanism in preclinical and clinical studies- -Data show CCR8 target is present with high prevalence and ...
The last time I spoke about Coherus Oncology (CHRS) it was with respect to a Seeking Alpha article entitled "Coherus: Biosimilar And Immuno-Oncology Pipeline Setup Could Pay Off". With respect to this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results